Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2000

View Archived Issues

Protein-peptide fusion stimulates anticancer activity without adjuvant

Researchers identify ACE2, the first human homologue of ACE

Eptifibatide reduces death, myocardial infarction in unstable angina

Male osteoporosis treated effectively with alendronate in two-year study

Parkinson's marked by loss of norepinephrine nerve terminals in the heart

New proxifan H3 antagonist selected as development candidate for ADHD and Alzheimer's disease

Novel duocarmycin derivative suitable for use in anticancer immunoconjugates

Toleragen candidate for antibody-mediated thrombosis effective in preclinical model

Oleander extract selectively kills human cancer cells via an effect on TRF2

Rabeprazole superior to ranitidine in erosive gastroesophageal reflux disease

Antibody and protein therapeutics for breast cancer sought by Eos and Biogen collaboration

Update on U.S. status of Zonagen's sexual dysfunction products

Celgene expands product pipeline and technology platform with Signal acquisition

OSI's ERF receptor inhibitor continues to demonstrate anticancer activity and good safety

Important new approval obtained for Actos

Potent hydroxamate-based MMP-2 inhibitors disclosed by Abbott

Serine protease inhibitors for asthma, pancreatitis designed by Ortho-McNeil scientists

Series of patents covers American Cyanamid's new TACE inhibitors

Technetium complexes and their use in cardiac imaging

Novel treatments for obesity under study at Lilly

Pfizer prepares acid-stable, broad-spectrum macrolide antibiotics

HEV vaccine technology licensed to SmithKline Beecham

Encouraging results reported for phenserine in multiple-dose safety trial

Pfizer initiates clinical program for pagoclone

Phase I/II clinical trial demonstrates safety and tolerability of GVAX lung cancer vaccine

New therapy for AIDS wasting receives orphan product designation from E.C.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.